Arrivent, Alphamab ink $615 5M multitarget ADC partnership bioworld.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bioworld.com Daily Mail and Mail on Sunday newspapers.
Under the agreement, Glenmark will get the license for KN035 (Envafolimab) in India, Asia Pacific, the Middle East, Africa, Russia, CIS, and Latin America, the company said in a statement.
Get latest articles and stories on Latest News at LatestLY. Glenmark Pharmaceuticals Ltd on Thursday said its arm Glenmark Specialty S A (GSSA) has signed a license agreement with Jiangsu Alphamab Biopharmaceuticals Co and 3D Medicines (Beijing) Co Ltd for KN035 (Envafolimab), used in cancer treatment. Latest News | Glenmark Inks Licensing Pact with Jiangsu Alphamab, 3D Medicines for Cancer Drug.